Fig. 3From: Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patientsOPLS-DA comparing pancreatic adenocarcinoma (PA) with pancreatic healthy tissue (PP). A two-class model including 53 samples without neoadjuvant chemotherapy: 9 samples of PP and 44 of PA. A clear distinction between the different classes of tissues is shown in this model (R2Y = 0.79; Q2 = 0.62)Back to article page